Drug Trial Radar · NCT03454646
Comparison of Therapeutic Strategies With Cholinesterase Inhibitors (SOS TRIAL)
Last checked: Nov 19, 2026Latest source record: Oct 6, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
1,205
Planned (sponsor's estimate)
Start
Jun 1, 2024
Primary completion
Apr 27, 2027
Study completion Sep 15, 2027
Sponsor
- Lead sponsor
- University Hospital, BordeauxAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Mar 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Cholinesterase inhibitors (CI) remain the only drugs with a recognized efficacy in mild to moderate Alzheimer's disease (AD) in spite of enormous research efforts. However, these drugs presented as "symptomatic treatment" of AD are considered as having only a weak effect on the course of AD. The reimbursement of these drugs is regularly challenged due to the lack of evidence for the impact of these drugs on milestones stages of AD evolution (survival without severe dementia, restriction in Basic Activities of Daily Living - BADL) and on major consequences in public health (hospitalization and institutionalization). The great majority of previous randomized controlled trials conducted with CI have had a too short duration and the end points were limited to cognition (ADAS Cog scale), IADL (Instrumental Activities of Daily Living) function and Global Impression of Change. New evidences from the DOMINO trial (1) conducted in UK, independently of the pharmaceutical industry, showed that the true effect of CI might be more to avoid or to delay the cognitive or functional decline in AD than to improve patients; the institutionalisation (2) was also delayed. However, this trial was conducted in patients with moderate to severe AD, and the interest of the drugs at the mild to moderate stage remains questionable. The investigators have shown that a good surrogate marker of survival without severe dementia would be an increase of ADAS Cog scale of more than six points (3). A post hoc reanalysis of the pivotal RCT with two CI showed that in mild to moderate patients, CI was associated with a 15% decrease of patients with a deterioration of ADAS-Cog of more than six points in six months. Thus at the beginning of dementia the real effect of CI might be more of delaying the cognitive and functional decline, than to improve the patients. The main objective of the SOS trial is to demonstrate that the benefit of CI at the early phase of dementia is the same as at the later phase.
Conditions
- Alzheimer Disease
- Cholinesterase Inhibitors
Interventions
cholinesterase inhibitors (CI) (donepezil, galantamine or rivastigmine)Drug
The choice of the treatment will be done by the specialist according to his habits; the specialist will monitor the treatment as usual. All the recruited patients will be treated by CI according to the recommendations of the French HAS and the clinician's habits to choose the type of CI and adjust the dosage. After a 6-month period under CI treatment, patients will be classified according to the evolution of the Mini Mental State Examination (MMSE) as "non-responders" or responders. Responders patients will continue their treatment according to the habits of the clinician. Non-responder patients will be included in the RCT, with individual randomization in two groups: one group who stops the CI, one group who continues the CI. All randomized patients will then be followed-up for two years with regular assessment of judgment criteria every 6 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The primary outcome is a combination of complete BADL dependency in bathing and dressing and/or institutionalization or death at 2 years after randomization.Time frame: at 30 months after patient's inclusion
Locations
31 sites in 1 country. Site status is shown where the registry gives one.
CHU d'Amiens Centre Mémoire Ressources Recherche
Amiens, France
CHU d'Angers Centre Mémoire Ressources Recherche
Angers, France
CHU de Bastia Centre Mémoire Ressources Recherche
Bastia, France
CHU de Besançon Centre Mémoire Ressources Recherche
Besançon, France
CHU de Bordeaux - Service de Neurologie - Centre Mémoire Ressources Recherche -
Bordeaux, France
CHRU Cavale Blanche Service de Gériatrie
Brest, France
Service de Neuropsychologie Hôpital Neurologique Pierre Wertheimer
Bron, France
CHU Côte de Nacre Service de neurologie et CMRR
Caen, France
CHU de Clermont Ferrand Centre Mémoire Ressources Recherche
Clermont-Ferrand, France
Hôpital Pasteur Service de Neurologie
Colmar, France
CHU de Dijon- CMRR
Dijon, France
Chu de Grenoble CMRR, Neurologie
Grenoble, France
Hôpital Roger Salengro CMRR
Lille, France
CHU Limoges Service de neurologie et CMRR
Limoges, France
AP-HM
Marseille, France
CHU Montpellier Hôpital Gui de Chauliac CMRR
Montpellier, France
CHU de Nantes Clinique Neurologique Hôpital GR Laennec
Nantes, France
Institut Claude Pompidou Centre Mémoire de Ressources et de Recherche
Nice, France
APHP Hôpital Broca
Paris, France
Hôpital Universitaire de la Pitié Salpêtrière Pavillon François Lhermitte
Paris, France
APHP Groupe Hospitalier Saint Louis Lariboisière Fernand Widal CMRR
Paris, France
CHU La Milétrie Pôle de Gériatrie
Poitiers, France
CHU Reims Hôpital Maison Blanche Court Séjour Gériatrique
Reims, France
CHU de Rennes - Hôpital Pontchaillou / Service de Neurologie
Rennes, France
CHU de Rouen Hôpital Charles Nicolle Service Neurologie
Rouen, France
Chu de Saint-Etienne, CMRR
Saint-Etienne, France
Chu de Strasbourg Hôpital Ka Robertsau Pôle de Gériatrie - CMRR
Strasbourg, France
Centre de Recherche Clinique du Gérontopôle Cité de la Santé
Toulouse, France
CHRU de Bretonneau Unité de gérontopsychiatrie
Tours, France
CHU Nancy Service de Gériatrie-CMRR
Vandœuvre-lès-Nancy, France
Hospice Civil de Lyon Hôpital des Charpennes
Villeurbanne, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.